Literature DB >> 34909452

Measurement of Bone Metastatic Tumor Growth by a Tibial Tumorigenesis Assay.

Baotong Zhang1,2,3, Xin Li4,5, Wei-Ping Qian3,6, Daqing Wu4,5, Jin-Tang Dong1,2,3.   

Abstract

Bone metastasis is a frequent and lethal complication of many cancer types (i.e., prostate cancer, breast cancer, and multiple myeloma), and a cure for bone metastasis remains elusive. To recapitulate the process of bone metastasis and understand how cancer cells metastasize to bone, intracardiac injection and intracaudal arterial animal models were developed. The intratibial injection animal model was established to investigate the communication between cancer cells and the bone microenvironment and to mimic the setting of prostate cancer patients with bone metastasis. Given that detailed protocols of intratibial injection and its quantitative analysis are still insufficient, in this protocol, we provide hands-on procedures for how to prepare cells, perform the tibial injection, monitor tibial tumor growth, and quantitatively evaluate the tibial tumors in pathological samples. This manuscript provides a ready-to-use experimental protocol for investigating cancer cell behaviors in bone and developing novel therapeutic strategies for bone metastatic cancer patients.
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Bone metastasis; Mouse model; Osteolysis; Prostate cancer; Tibial injection; Tumorigenesis

Year:  2021        PMID: 34909452      PMCID: PMC8635842          DOI: 10.21769/BioProtoc.4231

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  7 in total

Review 1.  Clinical features of metastatic bone disease and risk of skeletal morbidity.

Authors:  Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

Review 2.  Bone metastases.

Authors:  Robert E Coleman; Peter I Croucher; Anwar R Padhani; Philippe Clézardin; Edward Chow; Marie Fallon; Theresa Guise; Simone Colangeli; Rodolfo Capanna; Luis Costa
Journal:  Nat Rev Dis Primers       Date:  2020-10-15       Impact factor: 52.329

3.  Models of bone metastasis.

Authors:  J Preston Campbell; Alyssa R Merkel; S Kathryn Masood-Campbell; Florent Elefteriou; Julie A Sterling
Journal:  J Vis Exp       Date:  2012-09-04       Impact factor: 1.355

4.  A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries.

Authors:  Takahiro Kuchimaru; Naoya Kataoka; Kenji Nakagawa; Tatsuhiro Isozaki; Hitomi Miyabara; Misa Minegishi; Tetsuya Kadonosono; Shinae Kizaka-Kondoh
Journal:  Nat Commun       Date:  2018-07-30       Impact factor: 14.919

5.  Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.

Authors:  Baotong Zhang; Yixiang Li; Qiao Wu; Lin Xie; Benjamin Barwick; Changying Fu; Xin Li; Daqing Wu; Siyuan Xia; Jing Chen; Wei Ping Qian; Lily Yang; Adeboye O Osunkoya; Lawrence Boise; Paula M Vertino; Yichao Zhao; Menglin Li; Hsiao-Rong Chen; Jeanne Kowalski; Omer Kucuk; Wei Zhou; Jin-Tang Dong
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

6.  Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.

Authors:  Xin Li; Lajos Gera; Shumin Zhang; Yanhua Chen; Lei Lou; Lauren Marie Wilson; Zhong-Ru Xie; Giuseppe Sautto; Degang Liu; Alira Danaher; Kenza Mamouni; Yang Yang; Yuhong Du; Haian Fu; Omer Kucuk; Adeboye O Osunkoya; Jia Zhou; Daqing Wu
Journal:  Theranostics       Date:  2021-05-08       Impact factor: 11.556

7.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Authors:  Nicholas David James; Melissa R Spears; Noel W Clarke; David P Dearnaley; Johann S De Bono; Joanna Gale; John Hetherington; Peter J Hoskin; Robert J Jones; Robert Laing; Jason F Lester; Duncan McLaren; Christopher C Parker; Mahesh K B Parmar; Alastair W S Ritchie; J Martin Russell; Räto T Strebel; George N Thalmann; Malcolm D Mason; Matthew R Sydes
Journal:  Eur Urol       Date:  2014-10-06       Impact factor: 20.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.